ALSO READA 3-D approach to fighting cancer with cancer AstraZeneca lung cancer failure sparks 16 percent share fall AstraZeneca rebuilds cancer drug hopes with new lung data Alert granny spots eye cancer of baby brave heart ( May 14-21 is World Eye Cancer Awareness Week) Merck's immunotherapy, chemo mix shows extended lung cancer gains
Pharma major Dr Reddy's Laboratories Ltd on Tuesday launched Clofarabine injection, usually prescribed to treat a type of cancer of the white blood cells, in the US market.
Approved by the US Food and Drug Administration (USFDA), it is a therapeutic equivalent generic version of Clolar (clofarabine) injection.
The Clolar brand and generic had US sales of approximately $53 million MAT (Moving Annual Total) for the 12 months ended in September 2017, according to IMS Health, which provides information services for the healthcare industry.
Clofarabine injection is available in single-dose, 20 mL flint vials containing 20 mg of clofarabine in 20 mL of solution (1mg/mL), the Hyderabad-based firm said in a statement.
Clolar is a registered trademark of Genzyme Corporation.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)